These findings confirm our hypothesis that the combination of cisplatin and MLN4924 treatment induces JNK activation and downstream Bcl-xL down-regulation, which leads to apoptosis in urothelial carcinoma cells. Here, BCL2L1 is linked to urothelial carcinoma.